Session

IBD (Posters)

IN PATIENTS WITH CROHN'S DISEASE, FECAL CALPROTECTIN DROP-SLOPE DURING INDUCTION WITH USTEKINUMAB CAN AFFECT ITS LEVELS AND DISCRIMINATE THE NEED FOR INTENSIFICATION AT WEEK 52
IN PATIENTS WITH CROHN'S DISEASE, FECAL CALPROTECTIN DROP-SLOPE DURING INDUCTION WITH USTEKINUMAB CAN AFFECT ITS LEVELS AND DISCRIMINATE THE NEED FOR INTENSIFICATION AT WEEK 52

MAGNIFI-CD INDEX IS A STRONG PROGNOSTIC FACTOR IN PATIENTS WITH PERIANAL FISTULIZING CROHN’S DISEASE
MAGNIFI-CD INDEX IS A STRONG PROGNOSTIC FACTOR IN PATIENTS WITH PERIANAL FISTULIZING CROHN’S DISEASE

THE INTERACTION BETWEENSEROTONIN REUPTAKE TRANSPORTERAND BRAIN-DERIVED NEUROTROPHIC FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS
THE INTERACTION BETWEENSEROTONIN REUPTAKE TRANSPORTERAND BRAIN-DERIVED NEUROTROPHIC FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS

ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION
ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION

BERBERINE SUPPLEMENTATION SIGNIFICANTLY IMPROVED ANTI-TNF-ALPHA EFFICACY IN MURINE COLITISMICEHUMANIZED WITH NON-RESPONDER GUT MICROBIOTA
BERBERINE SUPPLEMENTATION SIGNIFICANTLY IMPROVED ANTI-TNF-ALPHA EFFICACY IN MURINE COLITISMICEHUMANIZED WITH NON-RESPONDER GUT MICROBIOTA

FACTORS ASSOCIATED WITH CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX IN CROHN’S DISEASE – A TERTIATY CENTER EXPERIENCE
FACTORS ASSOCIATED WITH CUMULATIVE BOWEL DAMAGE USING LEMANN INDEX IN CROHN’S DISEASE – A TERTIATY CENTER EXPERIENCE

REAL-LIFE EXPERIENCE OF ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF AGENTS AT TWO TERTIARY CARE PAEDIATRIC INFLAMMATORY BOWEL DISEASE CENTRES
REAL-LIFE EXPERIENCE OF ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF AGENTS AT TWO TERTIARY CARE PAEDIATRIC INFLAMMATORY BOWEL DISEASE CENTRES

CORRELATION OF THE PROMONITOR QUICK ADL LATERAL FLOW-BASED POINT OF CARE TEST TO QUANTIFY ADALIMUMAB IN A FINGER PRICK OR SERUM SAMPLES WITH THE REFERENCE ELISA TECHNIQUE
CORRELATION OF THE PROMONITOR QUICK ADL LATERAL FLOW-BASED POINT OF CARE TEST TO QUANTIFY ADALIMUMAB IN A FINGER PRICK OR SERUM SAMPLES WITH THE REFERENCE ELISA TECHNIQUE

IN HIGHLY REFRACTORY ULCERATIVE COLITIS PATIENTS, USTEKINUMAB IS A GOOD THERAPEUTIC OPTION
IN HIGHLY REFRACTORY ULCERATIVE COLITIS PATIENTS, USTEKINUMAB IS A GOOD THERAPEUTIC OPTION

THERAPEUTIC DRUG MONITORING: STANDARDIZATION OF PROMONITOR QUICK IFX AND PROMONITOR QUICK ADL POINT OF CARE TESTS WITH WHO INTERNATIONAL STANDARDS FOR THE QUANTIFICATION OF INFLIXIMAB AND ADALIMUMAB IN WHOLE BLOOD AND SERUM
THERAPEUTIC DRUG MONITORING: STANDARDIZATION OF PROMONITOR QUICK IFX AND PROMONITOR QUICK ADL POINT OF CARE TESTS WITH WHO INTERNATIONAL STANDARDS FOR THE QUANTIFICATION OF INFLIXIMAB AND ADALIMUMAB IN WHOLE BLOOD AND SERUM

IMPACT OF INFLAMMATORY BOWEL DISEASE ON THE QUALITY OF LIFE OF PATIENT’S HOUSEHOLD MEMBERS
IMPACT OF INFLAMMATORY BOWEL DISEASE ON THE QUALITY OF LIFE OF PATIENT’S HOUSEHOLD MEMBERS

ARTIFICIAL INTELLIGENCE IN HISTOPATHOLOGICAL DIAGNOSIS OF IBD – A PILOT STUDY
ARTIFICIAL INTELLIGENCE IN HISTOPATHOLOGICAL DIAGNOSIS OF IBD – A PILOT STUDY

FISTULOUS SKIN METASTASES IN CROHN'S DISEASE: A CASE REPORT AND REVIEW OF THE LITERATURE
FISTULOUS SKIN METASTASES IN CROHN'S DISEASE: A CASE REPORT AND REVIEW OF THE LITERATURE

TOWARDS A PERSONALIZED APPROACH IN ULCERATIVE COLITIS: ROLE OF OCTN1 IN PREDICTING DISEASE SEVERITY AND INDIVIDUAL RESPONSE TO THERAPY
TOWARDS A PERSONALIZED APPROACH IN ULCERATIVE COLITIS: ROLE OF OCTN1 IN PREDICTING DISEASE SEVERITY AND INDIVIDUAL RESPONSE TO THERAPY

OUTCOME PREDICTORS FOR VEDOLIZUMAB THERAPY IN CROHN’S DISEASE PATIENTS IN A REAL-WORLD SETTING
OUTCOME PREDICTORS FOR VEDOLIZUMAB THERAPY IN CROHN’S DISEASE PATIENTS IN A REAL-WORLD SETTING

SALIVARY EXOSOMES AGGRAVATE COLITIS BY REGULATING THE GUT IMMUNITY
SALIVARY EXOSOMES AGGRAVATE COLITIS BY REGULATING THE GUT IMMUNITY

EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS
EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS

IBD (Posters)  et al.

NEW-ONSET INFLAMMATORY BOWEL DISEASE DURING TREATMENT WITH THE ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY SECUKINUMAB. A CASE SERIES PRESENTATION
NEW-ONSET INFLAMMATORY BOWEL DISEASE DURING TREATMENT WITH THE ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY SECUKINUMAB. A CASE SERIES PRESENTATION

POOR SLEEP IN IBD IS ASSOCIATED WITH ACTIVE DISEASE, ANXIETY AND DEPRESSION, AND OUTCOMES SUCH AS INCREASED FATIGUE, INCREASED DISABILITY, AND POOR QUALITY OF LIFE
POOR SLEEP IN IBD IS ASSOCIATED WITH ACTIVE DISEASE, ANXIETY AND DEPRESSION, AND OUTCOMES SUCH AS INCREASED FATIGUE, INCREASED DISABILITY, AND POOR QUALITY OF LIFE

PERSONALISED AZITHROMYCIN+METRONIDAZOLE (PAZAZ), IN COMBINATION WITH STANDARD INDUCTION THERAPY, TO ACHIEVE A FAECAL MICROBIOME COMMUNITY STRUCTURE AND METAGENOME CHANGES ASSOCIATED WITH SUSTAINED REMISSION IN PAEDIATRIC CROHN’S DISEASE (CD): INITIAL RESU
PERSONALISED AZITHROMYCIN+METRONIDAZOLE (PAZAZ), IN COMBINATION WITH STANDARD INDUCTION THERAPY, TO ACHIEVE A FAECAL MICROBIOME COMMUNITY STRUCTURE AND METAGENOME CHANGES ASSOCIATED WITH SUSTAINED REMISSION IN PAEDIATRIC CROHN’S DISEASE (CD): INITIAL RESU

Item 41 - 60 / 612
1 2
3
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31